| RESEARCH-AGREEMENTS-KYOWA-KIRIN-CO-LTD |
RESEARCH-AGREEMENTS-KYOWA-KIRIN-CO-LTD |
85%
|
ts (continued) 9. License and Research Agreements Kyowa Kirin Co., Ltd. In August 2013, the Company entered into a collaboration and license agreement with Kyowa Kirin Co., Ltd., or KKC. Under the te… |
| MNPR |
Monopar Therapeutics Inc. |
72%
|
Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities … |
| RGNX |
REGENXBIO Inc. |
72%
|
Reciprocal relationship from RGNX graph: atent that will expire in 2034, one issued U.S. patent that will expire in 2038, one issued U.S. patent that will expire in 2039, one issued U.S. patent that … |
| SLDB |
Solid Biosciences Inc. |
72%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| SLDB |
Solid Biosciences Inc. |
72%
|
Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB graph: Reciprocal relationship from RARE graph: Reciprocal relationship from SLDB g… |
| AENOVA-HAUPT-PHARMA-WOLFRATSHAUSEN-GMBH |
AENOVA-HAUPT-PHARMA-WOLFRATSHAUSEN-GMBH |
62%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| BAXTER-PHARMACEUTICAL-SOLUTIONS-LLC |
BAXTER-PHARMACEUTICAL-SOLUTIONS-LLC |
62%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| CLINICAL-PRODUCT-CANDIDATES-REGENXBIO-INC |
CLINICAL-PRODUCT-CANDIDATES-REGENXBIO-INC |
62%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| COMPANY-LLC |
COMPANY-LLC |
62%
|
se increased $3.6 million for the year ended December 31, 2024, compared to the same period in 2023. These changes were primarily due to fluctuations in foreign exchange rates. (Provision for) Benefi… |
| DAIICHI-SANKYO-CO-LTD |
DAIICHI-SANKYO-CO-LTD |
62%
|
for our products and product candidates; • our ability to sell our products and product candidates on a named patient basis or through an equivalent mechanism and the amount of revenue generated from… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
er or not they are consummated. We may not be able to identify desirable acquisitions or investments or be successful in completing or realizing anticipated benefits from such transactions. We may ex… |
| ESJAY-PHARMA-LLC-ULTRAGENYX-PHARMACEUTICAL-INC |
ESJAY-PHARMA-LLC-ULTRAGENYX-PHARMACEUTICAL-INC |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| ESJAY-PHARMA-PRIVATE-LIMITED |
ESJAY-PHARMA-PRIVATE-LIMITED |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| EXHIBITS-INCORPORATED |
EXHIBITS-INCORPORATED |
62%
|
er or not they are consummated. We may not be able to identify desirable acquisitions or investments or be successful in completing or realizing anticipated benefits from such transactions. We may ex… |
| GENETX-BIOTHERAPEUTICS-LLC |
GENETX-BIOTHERAPEUTICS-LLC |
62%
|
ars) Accumulated Amortization Net Carrying Amount Indefinite-lived intangibles $ 129,000 — $ — $ 129,000 Finite-lived intangibles 62,275 9 ( 12,961 ) 49,314 Total intangible assets $ 191,275 — $ ( 12… |
| IOI-OLEO-GMBH |
IOI-OLEO-GMBH |
62%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| KYOWA-KIRIN-CO-LTD |
KYOWA-KIRIN-CO-LTD |
62%
|
ts (continued) 9. License and Research Agreements Kyowa Kirin Co., Ltd. In August 2013, the Company entered into a collaboration and license agreement with Kyowa Kirin Co., Ltd., or KKC. Under the te… |
| LEGAL-PROCEEDINGS-ULTRAGENYX-PHARMACEUTICAL-INC |
LEGAL-PROCEEDINGS-ULTRAGENYX-PHARMACEUTICAL-INC |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| NAVINTA-LLC-AUROBINDO-PHARMA-LIMITED-AUROBINDO-P |
NAVINTA-LLC-AUROBINDO-PHARMA-LIMITED-AUROBINDO-P |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| OCM-LS23-HOLDINGS |
OCM-LS23-HOLDINGS |
62%
|
statements presented, there have been no material changes to prior period estimates of revenues and expenses. We sold the right to receive certain royalty payments from net sales of Crysvita in certa… |
| ODIN-PHARMACEUTICALS-LLC |
ODIN-PHARMACEUTICALS-LLC |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| OSSIFI-MAB-LLC |
OSSIFI-MAB-LLC |
62%
|
d strategy and may encounter difficulties in allocating sufficient resources to sales and marketing of certain products. Further, as we launch additional products or as demand for our products change… |
| PRECLINICAL-PIPELINE-SOLID-BIOSCIENCES-INC |
PRECLINICAL-PIPELINE-SOLID-BIOSCIENCES-INC |
62%
|
ch was subsequently amended, with Baylor Research Institute, or BRI, under which we exclusively licensed certain intellectual property related to Dojolvi. The license includes patents, patent applica… |
| SOLID-BIOSCIENCES-INC |
SOLID-BIOSCIENCES-INC |
62%
|
er or not they are consummated. We may not be able to identify desirable acquisitions or investments or be successful in completing or realizing anticipated benefits from such transactions. We may ex… |
| SOMERSET-THERAPEUTICS-LLC |
SOMERSET-THERAPEUTICS-LLC |
62%
|
trategy and may encounter difficulties in allocating sufficient resources to sales and marketing of certain products. Further, as we launch additional products or as demand for our products change, o… |
| SOMERSET-THERAPEUTICS-LLC-SOMERSET-PHARMA-LLC |
SOMERSET-THERAPEUTICS-LLC-SOMERSET-PHARMA-LLC |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| SOMERSET-THERAPEUTICS-PRIVATE-LIMITED |
SOMERSET-THERAPEUTICS-PRIVATE-LIMITED |
62%
|
sults and cost of our clinical studies, nonclinical testing, and other related activities; • the cost of manufacturing clinical supplies, and establishing commercial supplies, of our product candidat… |
| WUXI-APPTECH-CO |
WUXI-APPTECH-CO |
62%
|
eement may also be less favorable or more costly than the terms we have with our current supplier. A delay in the commercialization of our products or the development of our product candidates or hav… |
